- Stocks
- Healthcare
- NYSE: BSX

Price (delayed)

$42.66

Market cap

$60.79B

P/E Ratio

55.4

Dividend/share

N/A

EPS

$0.77

Enterprise value

$67.93B

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology,

The P/E is 38% below the 5-year quarterly average of 88.9

Boston Scientific's gross profit has increased by 14% YoY and by 3.2% QoQ

The EPS has soared by 108% from the previous quarter but it has plunged by 71% YoY

Boston Scientific's net income has surged by 99% QoQ but it has shrunk by 69% YoY

BSX's quick ratio is down by 18% year-on-year and by 16% since the previous quarter

What are the main financial stats of BSX

Market
Valuations
Earnings

Shares outstanding

1.42B

Market cap

$60.79B

Enterprise value

$67.93B

Price to earnings (P/E)

55.4

Price to book (P/B)

3.69

Price to sales (P/S)

5.3

EV/EBIT

42.11

EV/EBITDA

19.19

EV/Sales

5.92

Revenue

$11.47B

EBIT

$1.61B

EBITDA

$3.54B

Free cash flow

$1.72B

Per share
Balance sheet
Liquidity

EPS

$0.77

Free cash flow per share

$1.21

Book value per share

$11.56

Revenue per share

$8.06

TBVPS

$9.71

Total assets

$31.88B

Total liabilities

$15.42B

Debt

$9.09B

Equity

$16.46B

Working capital

$2.21B

Debt to equity

0.55

Current ratio

1.55

Quick ratio

0.9

Net debt/EBITDA

2.02

Margins
Efficiency
Dividend

EBITDA margin

30.9%

Gross margin

67.4%

Net margin

10.1%

Operating margin

8.9%

Return on assets

3.5%

Return on equity

6.9%

Return on invested capital

9.2%

Return on capital employed

5.8%

Return on sales

14.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Boston Scientific stock price performed over time

Intraday

-0.72%

1 week

-4.9%

1 month

-0.14%

1 year

15.2%

YTD

0.42%

QTD

0.42%

How have Boston Scientific's revenue and profit performed over time

Revenue

$11.47B

Gross profit

$7.73B

Operating income

$1.02B

Net income

$1.16B

Gross margin

67.4%

Net margin

10.1%

Boston Scientific's operating income has soared by 118% from the previous quarter

BSX's operating margin has surged by 112% since the previous quarter

Boston Scientific's net income has surged by 99% QoQ but it has shrunk by 69% YoY

Boston Scientific's net margin has surged by 94% QoQ but it has shrunk by 72% YoY

What is Boston Scientific's growth rate over time

What is Boston Scientific stock price valuation

P/E

55.4

P/B

3.69

P/S

5.3

EV/EBIT

42.11

EV/EBITDA

19.19

EV/Sales

5.92

The EPS has soared by 108% from the previous quarter but it has plunged by 71% YoY

The P/E is 38% below the 5-year quarterly average of 88.9

The stock's price to book (P/B) is 21% less than its 5-year quarterly average of 4.7 but 2.5% more than its last 4 quarters average of 3.6

The equity has grown by 6% YoY and by 3.3% from the previous quarter

The revenue has increased by 13% YoY and by 2.4% from the previous quarter

BSX's P/S is 6% above its 5-year quarterly average of 5.0

How efficient is Boston Scientific business performance

The return on assets has surged by 106% since the previous quarter but it has dropped by 71% year-on-year

The return on equity has surged by 103% since the previous quarter but it has dropped by 72% year-on-year

BSX's ROIC has soared by 80% from the previous quarter

The ROS has soared by 74% from the previous quarter

What is BSX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BSX.

How did Boston Scientific financials performed over time

Boston Scientific's total assets is 107% more than its total liabilities

BSX's quick ratio is down by 18% year-on-year and by 16% since the previous quarter

BSX's current ratio is down by 17% year-on-year and by 7% since the previous quarter

Boston Scientific's debt is 45% lower than its equity

Boston Scientific's debt to equity has decreased by 8% YoY and by 3.5% from the previous quarter

The equity has grown by 6% YoY and by 3.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.